JP4757194B2 - 血管内皮増殖抑制遺伝子 - Google Patents

血管内皮増殖抑制遺伝子 Download PDF

Info

Publication number
JP4757194B2
JP4757194B2 JP2006519430A JP2006519430A JP4757194B2 JP 4757194 B2 JP4757194 B2 JP 4757194B2 JP 2006519430 A JP2006519430 A JP 2006519430A JP 2006519430 A JP2006519430 A JP 2006519430A JP 4757194 B2 JP4757194 B2 JP 4757194B2
Authority
JP
Japan
Prior art keywords
polypeptide
promoter
activity
amino acid
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006519430A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2005090574A1 (ja
Inventor
淳 松木
啓徳 中神
竜一 森下
安史 金田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenomIdea Inc
Original Assignee
GenomIdea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GenomIdea Inc filed Critical GenomIdea Inc
Priority to JP2006519430A priority Critical patent/JP4757194B2/ja
Publication of JPWO2005090574A1 publication Critical patent/JPWO2005090574A1/ja
Application granted granted Critical
Publication of JP4757194B2 publication Critical patent/JP4757194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006519430A 2004-03-19 2005-03-17 血管内皮増殖抑制遺伝子 Active JP4757194B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006519430A JP4757194B2 (ja) 2004-03-19 2005-03-17 血管内皮増殖抑制遺伝子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004081738 2004-03-19
JP2004081738 2004-03-19
PCT/JP2005/004836 WO2005090574A1 (fr) 2004-03-19 2005-03-17 Gène inhibant le développement endothélial vasculaire
JP2006519430A JP4757194B2 (ja) 2004-03-19 2005-03-17 血管内皮増殖抑制遺伝子

Publications (2)

Publication Number Publication Date
JPWO2005090574A1 JPWO2005090574A1 (ja) 2008-02-07
JP4757194B2 true JP4757194B2 (ja) 2011-08-24

Family

ID=34993706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519430A Active JP4757194B2 (ja) 2004-03-19 2005-03-17 血管内皮増殖抑制遺伝子

Country Status (2)

Country Link
JP (1) JP4757194B2 (fr)
WO (1) WO2005090574A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001252083A (ja) * 2000-03-14 2001-09-18 Japan Science & Technology Corp ヒト蛋白質とｃＤＮＡ［９］

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000018933A (ko) * 1998-09-07 2000-04-06 김승수 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자
EP1242443A4 (fr) * 1999-12-23 2005-06-22 Nuvelo Inc Nouveaux acides nucleiques et polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001252083A (ja) * 2000-03-14 2001-09-18 Japan Science & Technology Corp ヒト蛋白質とｃＤＮＡ［９］

Also Published As

Publication number Publication date
WO2005090574A1 (fr) 2005-09-29
JPWO2005090574A1 (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
JP4705026B2 (ja) 血管内皮増殖促進遺伝子
JP3746790B2 (ja) 抗ヒトＶＥＧＦ受容体Ｆ１ｔ―１モノクローナル抗体
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
WO2005084116A2 (fr) Nouveaux variants du canal calcique et leurs procedes d'utilisation
KR20040072626A (ko) 혈액학적 악성종양의 검출, 진단 및 치료용 조성물 및 방법
TR201813067T4 (tr) Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
US20110224133A1 (en) Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
JP2001514024A (ja) ５０個のヒト分泌タンパク質
CN112794895A (zh) 外源性atg10s蛋白在制备抗病毒药物中的应用
US11007248B2 (en) Suppression of allergic lung inflammation and hyperreactivity
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
EP1403367A1 (fr) Procede de test de medicament destine a traiter ou a prevenir des maladies telles que l'hyperlipemie
JP2023546133A (ja) 汎ＲＡＳ ｍＲＮＡがんワクチン
JP4757194B2 (ja) 血管内皮増殖抑制遺伝子
EP3874273A1 (fr) Biomarqueurs et méthodes d'utilisation de ces biomarqueurs pour détecter une lésion pulmonaire radio-induite
JPWO2004046353A1 (ja) 所望の機能的性質を有する核酸の単離方法およびそのためのキット
US8686127B2 (en) Apoptosis inducer
RU2813731C2 (ru) Новый коронавирус рыб
WO2005073385A1 (fr) Composition et méthode pour augmenter le rendement du tranfert de gênes
US20090304708A1 (en) Preparation for the Prevention and/or Treatment of a Tissue Change of Mesenchymal Origin
JP2003500336A (ja) （自己）免疫疾患の治療におけるアポトーシス誘発剤の使用
JP2001512325A (ja) 改変型レチノブラストーマ腫瘍抑制タンパク質
US20080064652A1 (en) Methods and compositions for treating hypercholesterolemia
US6790936B1 (en) CAI resistance proteins and uses thereof
NG PING PING Functional studies of adenoviral-mediated gene expression of CD157

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110531

R150 Certificate of patent or registration of utility model

Ref document number: 4757194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140610

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250